Reliability, validity, and sensitivity of Japanese version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument: application to efficacy assessment of intravenous immunoglobulin administration.

Objective This study aimed to develop and assess the reliability, validity, and sensitivity of Japanese version of the University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (GIT) Instrument 2.0 (the GIT score), as an evaluation tool for GIT symptoms in systemic sclerosis (SSc). Methods Japanese version of the GIT score was constructed using the forward-backward method. The reliability and validity of this instrument were evaluated in a cohort of 38 SSc patients. Correlation analysis was conducted to assess the relationship between the GIT score and existing patient-reported outcome measures. Additionally, the sensitivity of the GIT score was examined by comparing GIT scores before and after intravenous immunoglobulin (IVIG) administration in 10 SSc-myositis overlap patients, as IVIG has recently demonstrated effectiveness in alleviating GIT symptoms of SSc. Results Japanese version of the GIT score exhibited internal consistency and a significant association with the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease. Furthermore, the total GIT score, as well as the reflux and distention/bloating subscales, displayed moderate correlations with the EQ-5D pain/discomfort subscale, Short Form-36 body pain subscale, and its physical component summary. Notably, following IVIG treatment, there was a statistically significant reduction in the total GIT score and most of the subscales. Conclusion We firstly validated Japanese version of the GIT score in Japanese SSc patients in real-world clinical settings. This instrument holds promise for application in future clinical trials involving this patient population.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2023. ;https://doi.org/10.1101/2023 The cut-off value of each autoantigen was determined based on the mean + 3 standard 1 8 9 deviation (SD) of healthy controls.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2023. ;https://doi.org/10.1101https://doi.org/10. /2023

5
The EQ-5D questionnaire with five levels is a generic instrument to quantify 2 2 6 HRQOL.
[26] The EuroQoL Group developed and tested this tool for the purpose of 2 2 7 providing measurable health outcomes. In an initial study with SSc patients, the Italian 2 2 8 version of this tool proved to be valid.
[12] The EQ-5D is composed of two primary 2 2 9 components: the first section, known as the EQ-5D profile, generates a health profile 2 3 0 derived from a descriptive system. This system defines health based on five dimensions: 2 3 1 'mobility', 'self-care', 'usual activities', 'pain or discomfort', and 'anxiety or depression'.

3 2
Each dimension offers three response categories indicating no problems, some problems,  which is a self-report questionnaire used to assess the frequency and severity of 2 3 9 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  We analyzed average scores, SDs, ranges, and the percentage of missing data.

4 8
The floor and ceiling effects of the GIT scorewere determined by calculating the 2 4 9 9 7 levels of TNF-α or IL-6 and the reflux subscale, as illustrated in Figure 1A and 1B.

9 8
Additionally, a significant correlation was found between serum levels of VEGF and the 2 9 9 social functioning or constipation subscales, as depicted in Figure 1C and 1D. subscales, except for fecal soilage and constipation ( Figure 2B).

1 0
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

2 3
When contrasted with the original study utilizing the English version, [9] 3 2 4 several baseline differences in the study population were observed ( Table 1). The

2 5
Japanese version assessment was conducted on a smaller patient population (n=38 vs. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

2
Alternatively, one could interpret our study as having enrolled individuals with SSc 3 3 3 who had comparatively milder disease manifestations and lesser health impairments.

4
This interpretation finds support in our assessment of HRQOL, revealing a mean SF-36 3 3 9 An advantage of this study is the multi-dimensional immunophenotyping 3 4 0 conducted, which encompassed assessments of serum cytokine levels and autoantibody 3 4 1 profiles, aligned with the GIT score outcomes. As a result, we found that the serum 3 4 2 levels of TNF-α, IL-6, and VEGF were significantly correlated with the specific 3 4 3 subclass of the GIT score (Figure 1)  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint  set," J. Natl. Inst. Public Heal., vol. 64, no. 1, pp. 47-55, 2015. 4 9 5 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2023. ; https://doi.org/10.1101/2023.09.19.23295773 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. analyzed on day 1 and day 7. IVIG 2 g/kg was administered over 5 days (day 2-6). (B)

4 5
The total GIT score and subscales before and after IVIG administration. P values were . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2023. ;https://doi.org/10.1101https://doi.org/10. /2023  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2023. ; Table 1. Background of the patients for reliability and validity assessment. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

CC-BY 4.0 International license
It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was not certified by peer review)    is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2023. ;